NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/transmed ...

NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/transmedics-gro ...

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for alleged misconduct during the Class Period from February 28, 2023, to January 10, 2025, with a lead plaintiff deadline set for April 15, 2025 [1]. Allegations Against TransMedics - The complaint alleges that TransMedics engaged in unethical practices, including the use of kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [3]. - It is claimed that TransMedics engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight, which increased the company's regulatory risk [3]. Lead Plaintiff Process - Investors in TransMedics can seek to be appointed as a lead plaintiff representative by April 15, 2025, or may choose to remain absent from the class [4]. - The lead plaintiff will represent the interests of all class members and select counsel to direct the litigation [4].

PHILADELPHIA, March 6, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) on behalf of purchasers of TransMedics securities between February 28, 2023 through January 10, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired TRANSMEDICS securities during the Class Period may, no later than APRIL 15, 2025, seek to be appointed as a l ...

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Investors have until April 15, 2025, to ask the Court to b ...

NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=134056&from=4CLASS PERIOD: Febru ...

Core Viewpoint - The TransMedics Group, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misconduct including fraudulent practices and safety issues [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Jewik v. TransMedics Group, Inc., and covers purchasers of TransMedics securities from February 28, 2023, to January 10, 2025 [1]. - Investors have until April 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [3]. Group 2: Allegations Against TransMedics - Specific allegations include unsafe practices and a lack of safety oversight, which increased regulatory scrutiny risks [3]. - A letter from U.S. Representative Paul Gosar on February 21, 2024, accused TransMedics of misconduct, leading to a decline in stock price following its public disclosure [4]. - A report from Scorpion Capital on January 10, 2025, further accused TransMedics of overbilling and providing rejected organs to patients, resulting in additional stock price declines [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased TransMedics securities during the class period to seek lead plaintiff status [6]. - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in related class action cases [7].

NEW YORK, March 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/transmedics-gro ...

Company Overview - TransMedics' stock has shown a rebound in recent months, supported by stronger transplant volumes and reduced competition concerns [1] - Despite the rebound, the share price remains low relative to the company's guidance, indicating potential overvaluation of long-term targets [1] Investment Strategy - Narweena, an asset manager led by Richard Durant, focuses on identifying market dislocations due to misinterpretations of long-term business prospects [1] - The firm aims for excess risk-adjusted returns by targeting businesses with secular growth opportunities in markets with high entry barriers [1] - Narweena's investment approach emphasizes company and industry fundamentals to uncover unique insights, with a preference for smaller cap stocks [1] Market Dynamics - An aging population with low growth and stagnating productivity is expected to create new investment opportunities, differing from past trends [1] - Many industries may experience stagnation or secular decline, which could paradoxically enhance business performance due to reduced competition [1] - The economy is increasingly influenced by asset-light businesses, leading to a declining need for infrastructure investments [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premiums over time [1]

NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=132977&from=4 CLASS PERIOD: Febr ...